NOX4 and cardiac hypertrophy: Cardiac-specific deletion of NOX4 in transgenic mouse models subjected to TAC led to improved LV contractile function and a reduction in cardiac hypertrophy, fibrosis and apoptosis [4,60] (Table 4).